Efficacy

Fampyra (Fampridine) and Its Efficacy in Multiple Sclerosis

Fampyra, known generically as fampridine, is a medication approved for use in improving walking in patients with Multiple Sclerosis (MS). MS is a chronic, often disabling disease that attacks the central nervous system. The efficacy of Fampyra in MS is primarily observed in its ability to improve walking speed in some patients. Clinical trials have demonstrated that a subset of individuals with MS experience a significant improvement in walking speed and endurance when taking Fampyra. This is believed to be due to the drug’s action as a potassium channel blocker, which can help improve nerve signal conduction in damaged nerves.

However, it is important to note that Fampyra does not work for everyone with MS, and its benefits on walking ability vary among individuals. The drug is typically prescribed after an evaluation of walking ability and may include a trial period to determine its effectiveness for the patient. The improvements in walking can have a meaningful impact on the quality of life for those who respond positively to the treatment.

Tysabri (Natalizumab) and Its Efficacy in Multiple Sclerosis

Tysabri, with the active ingredient natalizumab, is another medication used in the treatment of Multiple Sclerosis. It is particularly indicated for the treatment of relapsing forms of MS to slow the progression of physical disability and decrease the frequency of clinical exacerbations. The efficacy of Tysabri is attributed to its mechanism of action as a monoclonal antibody that binds to the alpha-4 subunit of integrins expressed on the surface of leukocytes. This binding prevents the migration of potentially damaging immune cells across the blood-brain barrier into the central nervous system, where they could cause inflammation and demyelination.

Clinical trials have shown that Tysabri significantly reduces the annual relapse rate and slows the progression of disability in individuals with relapsing-remitting MS. Additionally, MRI scans have revealed that patients on Tysabri have fewer new or enlarging brain lesions compared to those not taking the medication. Despite its efficacy, Tysabri is generally recommended for patients who have not responded adequately to, or cannot tolerate, other treatments for MS due to the risk of a rare but serious brain infection known as progressive multifocal leukoencephalopathy (PML).